Answer
Breast-feeding should be discontinued during futibatinib (Lytgobi) treatment and for 1 week after the last dose because a risk to breast-fed newborns or infants cannot be excluded.
Sources for this answer
- Lytgobi 4 mg film-coated tabletsTaiho Pharma Europe Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 3Document updated
Sources checked